Progress in the development of human parainfluenza virus vaccines

Expert Review of Respiratory Medicine

Volumn 5, Issue 4, 2011, Pages 515-526

  Schmidt, Alexander C ^a   Schaap Nutt, Anne ^a   Bartlett, Emmalene J ^a   Schomacker, Henrick ^a   Boonyaratanakornkit, Jim ^a   Karron, Ruth A ^b   Collins, Peter L ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

acute respiratory illness; clinical trial; intranasal; live attenuated; parainfluenza virus vaccine; pediatric; vaccine

Indexed keywords

BOVINE PARAINFLUENZA VIRUS SEROTYPE 3 VACCINE; CHIMERIC BOVINE/HUMAN PARAINFLUENZA VIRUS SEROTYPE 3 RESPIRATORY SYNCYTIAL VIRUS F VACCINE; HUMAN PARAINFLUENZA VIRUS SEROTYPE 1 VACCINE; HUMAN PARAINFLUENZA VIRUS SEROTYPE 2 VACCINE; HUMAN PARAINFLUENZA VIRUS SEROTYPE 3 COLD PASSAGED 45 VACCINE; MEDI 534; MEDI 560; PARAINFLUENZA VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG;

ACUTE RESPIRATORY TRACT DISEASE; CHILD CARE; CLINICAL RESEARCH; COMORBIDITY; COUGHING; DRUG TOLERABILITY; HOSPITALIZATION; HUMAN; IMMUNE RESPONSE; OTITIS MEDIA; PARAINFLUENZA VIRUS 1; PARAINFLUENZA VIRUS 2; PARAINFLUENZA VIRUS 3; PARAINFLUENZA VIRUS INFECTION; REVIEW; RHINITIS; SEROTYPE; VIRAL TROPISM;

EID: 80052620543     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.11.32     Document Type: Review

References (101)

1. Black RE, Cousens S, Johnson HL et al. Global, regional and national causes of child mortality in 2008: a systematic analysis. Lancet 375(9730), 1969-1987 (2010).
2. O'Brien KL, Wolfson LJ, Watt JP et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374(9693), 893-902 (2009).
3. Watt JP, Wolfson LJ, O'Brien KL et al. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet 374(9693), 903-911 (2009).
4. Mullins JA, Erdman DD, Weinberg GA et al. Human metapneumovirus infection among children hospitalized with acute respiratory illness. Emerg. Infect. Dis. 10(4), 700-705 (2004). (Pubitemid 38420304)
5. Nair H, Nokes DJ, Gessner BD et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375(9725), 1545-1555 (2010).
6. Murphy BR, Prince GA, Collins PL et al. Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses. Virus Res. 11(1), 1-15 (1988).
7. Weinberg GA, Hall CB, Iwane MK et al. Parainfluenza virus infection of young children: estimates of the population-based burden of hospitalization. J. Pediatr. 154(5), 694-699 (2009).
8. Hall CB, Weinberg GA, Iwane MK et al. The burden of respiratory syncytial virus infection in young children. N. Engl. J. Med. 360(6), 588-598 (2009).
9. Poehling KA, Talbot HK, Williams JV et al. Impact of a school-based influenza immunization program on disease burden: comparison of two Tennessee counties. Vaccine 27(20), 2695-2700 (2009).
10. Forster J, Ihorst G, Rieger CH et al. Prospective population-based study of viral lower respiratory tract infections in children under 3 years of age (the PRI.DE study). Eur. J. Pediatr. 163(12), 709-716 (2004). (Pubitemid 40064377)
11. Marx A, Torok TJ, Holman RC, Clarke MJ, Anderson LJ. Pediatric hospitalizations for croup (laryngotracheobronchitis): biennial increases associated with human parainfluenza virus 1 epidemics. J. Infect. Dis. 176, 1423-1427 (1997). (Pubitemid 27518139)
12. Bjornson CL, Johnson DW. Croup. Lancet 371(9609), 329-339 (2008). (Pubitemid 351754788)
13. Rosychuk RJ, Klassen TP, Metes D, Voaklander DC, Senthilselvan A, Rowe BH. Croup presentations to emergency departments in Alberta, Canada: a large population-based study. Pediatr. Pulmonol. 45(1), 83-91 (2010).
14. Fry AM, Curns AT, Harbour K, Hutwagner L, Holman RC, Anderson LJ. Seasonal trends of human parainfluenza viral infections: United States, 1990-2004. Clin. Infect. Dis. 43(8), 1016-1022 (2006). (Pubitemid 44631102)
15. Glezen WP, Frank AL, Taber LH, Kasel JA. Parainfluenza virus type 3: seasonality and risk of infection and reinfection in young children. J. Infect. Dis. 150(6), 851-857 (1984). (Pubitemid 15182138)
16. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. 352(17), 1749-1759 (2005). (Pubitemid 40570923)
17. Wendt CH, Weisdorf DJ, Jordan MC, Balfour HH Jr, Hertz MI. Parainfluenza virus respiratory infection after bone marrow transplantation. N. Engl. J. Med. 326(14), 921-926 (1992).
18. Maziarz RT, Sridharan P, Slater S et al. Control of an outbreak of human parainfluenza virus 3 in hematopoietic stem cell transplant recipients. Biol. Blood Marrow Transpl. 16(2), 192-198 (2010).
19. Piralla A, Percivalle E, Di Cesare-Merlone A, Locatelli F, Gerna G. Multicluster nosocomial outbreak of parainfluenza virus type 3 infection in a pediatric oncohematology unit: a phylogenetic study. Haematologica 94(6), 833-839 (2009).
20. Nichols WG, Erdman DD, Han A, Zukerman C, Corey L, Boeckh M. Prolonged outbreak of human parainfluenza virus 3 infection in a stem cell transplant outpatient department: insights from molecular epidemiologic analysis. Biol. Blood Marrow Transpl. 10(1), 58-64 (2004). (Pubitemid 38145740)
21. Jalal H, Bibby DF, Bennett J et al. Molecular investigations of an outbreak of parainfluenza virus type 3 and respiratory syncytial virus infections in a hematology unit. J. Clin. Microbiol. 45(6), 1690-1696 (2007). (Pubitemid 46933893)
22. Campbell AP, Chien JW, Kuypers J et al. Respiratory virus pneumonia after hematopoietic cell transplantation (HCT): associations between viral load in bronchoalveolar lavage samples, viral RNA detection in serum samples and clinical outcomes of HCT. J. Infect. Dis. 201(9), 1404-1413 (2010).
23. Berkley JA, Munywoki P, Ngama M et al. Viral etiology of severe pneumonia among Kenyan infants and children. JAMA 303(20), 2051-2057 2010).
24. Reed G, Jewett PH, Thompson J, Tollefson S, Wright PF. Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children t5 years old. J. Infect. Dis. 175(4), 807-813 (1997). (Pubitemid 27142952)
25. Suzuki T, Portner A, Scroggs RA et al. Receptor specificities of human respiroviruses. J. Virol. 75(10), 4604-4613 (2001). (Pubitemid 32381502)
26. Zhang L, Bukreyev A, Thompson CI et al. Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium. J. Virol. 79(2), 1113-1124 (2005). (Pubitemid 40053894)
27. Karron RA, Collins PL. Parainfluenza viruses. In:Fields Virology. Knipe DM, Howley PM (Eds.) Lippincott Williams & Wilkins, PA, USA, 1497-1526 (2007).
28. Murphy BR. Current approaches to the development of vaccines effective against parainfluenza viruses. Bull. World Health Organ. 66(3), 391-397 (1988).
29. Bartlett EJ, Cruz AM, Boonyaratanakornkit J et al. A novel human parainfluenza virus type 1 (HPIV1) with separated P and C genes is useful for generating C gene mutants for evaluation as live-attenuated virus vaccine candidates. Vaccine 28(3), 767-779 (2010).
30. Boonyaratanakornkit J, Bartlett E, Schomacker H et al. The C proteins of human parainfluenza virus type 1 limit double stranded RNA accumulation that would otherwise trigger MDA5 and PKR activation. J. Virol. 85(4), 1495-1506 (2011).
31. Boonyaratanakornkit JB, Bartlett EJ, Amaro-Carambot E, Collins PL, Murphy BR, Schmidt AC. The C proteins of human parainfluenza virus type 1 (HPIV1) control the transcription of a broad array of cellular genes that would otherwise respond to HPIV1 infection. J. Virol. 83(4), 1892-1910 (2009).
32. Schaap-Nutt A, Scull MA, Schmidt AC, Murphy BR, Pickles RJ. Growth restriction of an experimental live attenuated human parainfluenza virus type 2 vaccine in human ciliated airway epithelium in vitro parallels attenuation in African green monkeys. Vaccine 28(15), 2788-2798 (2010).
33. Wilson J, Rowlands K, Rockett K et al. Genetic variation at the IL10 gene locus is associated with severity of respiratory syncytial virus bronchiolitis. J. Infect. Dis. 191(10), 1705-1709 (2005). (Pubitemid 40656759)
34. Crowe JE Jr, Williams JV. Immunology of viral respiratory tract infection in infancy. Paediatr. Respir. Rev. 4(2), 112-119 (2003). (Pubitemid 36665479)
35. Bartlett EJ, Hennessey M, Skiadopoulos MH et al. The role of interferon in the replication of human parainfluenza virus type 1 wild type and mutant viruses in human ciliated airway epithelium. J. Virol (2008).
36. Gitlin L, Benoit L, Song C et al. Melanoma differentiation-associated gene 5 (MDA5) is involved in the innate immune response to Paramyxoviridae infection in vivo. PLoS Pathog. 6(1), e1000734 (2010).
37. + T cells. J. Immunol. 149(4), 1319-1325 (1992).
38. Spriggs MK, Murphy BR, Prince GA, Olmsted RA, Collins PL. Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity. J. Virol. 61(11), 3416-3423 (1987). (Pubitemid 17152163)
39. Hall CB, Douglas RG Jr, Simons RL, Geiman JM. Interferon production in children with respiratory syncytial, influenza and parainfluenza virus infections. J. Pediatr. 93(1), 28-32 (1978). (Pubitemid 8351863)
40. + T cells requires direct targeting to virus-infected epithelium. Eur. J. Immunol. 25(1), 111-116 (1995).
41. + T cell memory. J. Immunol. 164(6), 3274-3282 (2000). (Pubitemid 30148991)
42. + T cells to be activated by residual antigen. J. Exp. Med. 207(6), 1153-1160 (2010).
43. Smith CB, Purcell RH, Bellanti JA, Chanock RM. Protective effect of antibody to parainfluenza type 1 virus. N. Engl. J. Med. 275(21), 1145-1152 (1966).
44. Tremonti LP, Lin JS, Jackson GG. Neutralizing activity in nasal secretions and serum in resistance of volunteers to parainfluenza virus type 2. J. Immunol. 101(3), 572-577 (1968).
45. Karron RA, Singleton RJ, Bulkow L et al. Severe respiratory syncytial virus disease in Alaska native children. RSV Alaska Study Group. J. Infect. Dis. 180(1), 41-49 (1999). (Pubitemid 29293915)
46. Malley R, DeVincenzo J, Ramilo O et al. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J. Infect. Dis. 178(6), 1555-1561 (1998). (Pubitemid 28558122)
47. Karron RA, Belshe RB, Wright PF et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants. Pediatr. Infect. Dis. J. 22(5), 394-405 (2003). (Pubitemid 36578739)
48. Shinoff JJ, O'Brien KL, Thumar B et al. Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus. J. Infect. Dis. 198(7), 1007-1015 (2008).
49. Crowe JE Jr. Influence of maternal antibodies on neonatal immunization against respiratory viruses. Clin. Infect. Dis. 33(10), 1720-1727 (2001).
50. Smith CB, Bellanti JA, Chanock RM. Immunoglobulins in serum and nasal secretions following infection with type 1 parainfluenza virus and injection of inactivated vaccines. J. Immunol. 99(1), 133-141 (1967).
51. Wright PF, Karron RA, Belshe RB et al. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine 25(42), 7372-7378 (2007). (Pubitemid 47484016)
52. Karron RA, Wright PF, Belshe RB et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J. Infect. Dis. 191(7), 1093-1104 (2005). (Pubitemid 40404368)
53. Wright PF, Karron RA, Belshe RB et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J. Infect. Dis. 182(5), 1331-1342 (2000).
54. Zemlin M, Hoersch G, Zemlin C et al. The postnatal maturation of the immunoglobulin heavy chain IgG repertoire in human preterm neonates is slower than in term neonates. J. Immunol. 178(2), 1180-1188 (2007). (Pubitemid 46095192)
55. Delgado MF, Coviello S, Monsalvo AC et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat. Med. 15(1), 34-41 (2009).
56. Kallewaard NL, McKinney BA, Gu Y, Chen A, Prasad BV, Crowe JE Jr. Functional maturation of the human antibody response to rotavirus. J. Immunol. 180(6), 3980-3989 (2008).
57. Murphy BR, Olmsted RA, Collins PL, Chanock RM, Prince GA. Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses. J. Virol. 62(10), 3907-3910 (1988).
58. Premenko-Lanier M, Hodge G, Rota P, Tamin A, Bellini W, McChesney M. Maternal antibody inhibits both cellular and humoral immunity in response to measles vaccination at birth. Virology 350(2), 429-432 (2006). (Pubitemid 43949419)
59. Belshe RB, Hissom FK. Cold adaptation of parainfluenza virus type 3: induction of three phenotypic markers. J. Med. Virol. 10(4), 235-242 (1982). (Pubitemid 13217870)
60. Durbin AP, Hall SL, Siew JW, Whitehead SS, Collins PL, Murphy BR. Recovery of infectious human parainfluenza virus type 3 from cDNA. Virology 235, 323-332 (1997). (Pubitemid 27394345)
61. Skiadopoulos MH, Surman S, Tatem JM et al. Identification of mutations contributing to the temperature-sensitive, cold-adapted and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine. J. Virol. 73(2), 1374-1381 (1999). (Pubitemid 29036792)
62. Karron RA, Wright PF, Newman FK et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children. J. Infect. Dis. 172(6), 1445-1450 (1995).
63. Belshe RB, Newman FK, Tsai TF et al. Phase II evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old. J. Infect. Dis. 189(3), 462-470 (2004). (Pubitemid 38210583)
64. Belshe RB, Newman FK, Anderson EL et al. Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children. J. Infect. Dis. 190(12), 2096-2103 (2004). (Pubitemid 39636356)
65. Bernstein D, Charenkavanich S, Falloon J. Safety profile, immunogenicity and viral shedding of rHPIV3cp45, a live, attenuated human parainfluezavirus type 3 (PIV3) vaccine. In: International RSV Symposium. GCO BV, Rotterdam, The Netherlands, 147 (2010).
66. van Wyke Coelingh KL, Winter CC, Tierney EL, London WT, Murphy BR. Attenuation of bovine parainfluenza virus type 3 in nonhuman primates and its ability to confer immunity to human parainfluenza virus type 3 challenge. J. Infect. Dis. 157(4), 655-662 (1988). (Pubitemid 18093723)
67. Karron RA, Makhene M, Gay K, Wilson MH, Clements ML, Murphy BR. Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants. Pediatr. Infect. Dis. J. 15(8), 650-654 (1996). (Pubitemid 26271970)
68. Greenberg DP, Walker RE, Lee MS et al. A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy. J. Infect. Dis. 191(7), 1116-1122 (2005). (Pubitemid 40404370)
69. Schmidt AC, McAuliffe JM, Huang A et al. Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates. J. Virol. 74(19), 8922-8929 (2000).
70. Haller AA, Miller T, Mitiku M, Coelingh K. Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector. J. Virol. 74(24), 11626-11635 (2000). (Pubitemid 32222311)
71. Tang RS, MacPhail M, Schickli JH et al. Parainfluenza virus type 3 expressing the native or soluble fusion (F) protein of respiratory syncytial virus (RSV) confers protection from RSV infection in African green monkeys. J. Virol. 78(20), 11198-11207 (2004). (Pubitemid 39299659)
72. Tang RS, Spaete RR, Thompson MW et al. Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity and enhanced disease and initial clinical testing in healthy adults. Vaccine 26(50), 6373-6382 (2008).
73. Schmidt AC, McAuliffe JM, Murphy BR, Collins PL. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. J. Virol. 75(10), 4594-4603 (2001). (Pubitemid 32381501)
74. Schmidt AC, Wenzke DR, McAuliffe JM et al. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone. J. Virol. 76(3), 1089-1099 (2002). (Pubitemid 34066413)
75. Gomez M, Mufson MA, Dubovsky F, Knightly C, Zeng W, Losonsky G. Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children. Pediatr. Infect. Dis. J. 28(7), 655-658 (2009).
76. Bernstein D, Malkin E, Charenkavanich S, Dubovsky F. Safety profile, immunogenicity and viral shedding of MEDI-534, a live, attenuated respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccine in RSV/PIV3 seronegative children. Presented at: International RSV Symposium. GCO BV, Rotterdam, The Netherlands, 2-5 December 2010.
77. Tao T, Durbin AP, Whitehead SS, Davoodi F, Collins PL, Murphy BR. Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1. J. Virol. 72(4), 2955-2961 (1998). (Pubitemid 28175533)
78. Skiadopoulos MH, Tao T, Surman SR, Collins PL, Murphy BR. Generation of a parainfluenza virus type 1 vaccine candidate by replacing the HN and F glycoproteins of the live-attenuated PIV3 cp45 vaccine virus with their PIV1 counterparts. Vaccine 18(5-6), 503-510 (1999). (Pubitemid 29462607)
79. Skiadopoulos MH, Tatem JM, Surman SR et al. The recombinant chimeric human parainfluenza virus type 1 vaccine candidate, rHPIV3-1cp45, is attenuated, immunogenic and protective in African green monkeys. Vaccine 20(13), 1846-1852 (2002). (Pubitemid 34242842)
80. Newman JT, Surman SR, Riggs JM et al. Sequence analysis of the Washington/1964 strain of human parainfluenza virus type 1 (HPIV1) and recovery and characterization of wild-type recombinant HPIV1 produced by reverse genetics. Virus Genes 24(1), 77-92 (2002). (Pubitemid 34229615)
81. McAuliffe JM, Surman SR, Newman JT et al. Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitro. J. Virol. 78(4), 2029-2036 (2004). (Pubitemid 38176734)
82. Newman JT, Riggs JM, Surman SR et al. Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses. J. Virol. 78(4), 2017-2028 (2004). (Pubitemid 38176733)
83. Bartlett EJ, Amaro-Carambot E, Surman SR et al. Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys. Vaccine 23(38), 4631-4646 (2005). (Pubitemid 41132813)
84. Bartlett EJ, Amaro-Carambot E, Surman SR, Collins PL, Murphy BR, Skiadopoulos MH. Introducing point and deletion mutations into the P/C gene of human parainfluenza virus type 1 (HPIV1) by reverse genetics generates attenuated and efficacious vaccine candidates. Vaccine 24(14), 2674-2684 (2006). (Pubitemid 43290400)
85. Van Cleve W, Amaro-Carambot E, Surman SR et al. Attenuating mutations in the P/C gene of human parainfluenza virus type 1 (HPIV1) vaccine candidates abrogate the inhibition of both induction and signaling of type I interferon (IFN) by wild-type HPIV1. Virology 352(1), 61-73 (2006). (Pubitemid 44164412)
86. Bartlett EJ, Castano A, Surman SR, Collins PL, Skiadopoulos MH, Murphy BR. Attenuation and efficacy of human parainfluenza virus type 1 (HPIV1) vaccine candidates containing stabilized mutations in the P/C and L genes. Virol. J. 4(1), 67 (2007).
87. Slobod KS, Shenep JL, Lujan-Zilbermann J et al. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults. Vaccine 22(23-24), 3182-3186 (2004). (Pubitemid 39037223)
88. Skiadopoulos MH, Biacchesi S, Buchholz UJ et al. The two major human metapneumovirus genetic lineages are highly related antigenically and the fusion (F) protein is a major contributor to this antigenic relatedness. J. Virol. 78(13), 6927-6937 (2004). (Pubitemid 38781531)
89. Kawano M, Kaito M, Kozuka Y et al. Recovery of infectious human parainfluenza type 2 virus from cDNA clones and properties of the defective virus without V-specific cysteine-rich domain. Virology 284(1), 99-112 (2001). (Pubitemid 32476699)
90. Skiadopoulos MH, Vogel L, Riggs JM, Surman SR, Collins PL, Murphy BR. The genome length of human parainfluenza virus type 2 follows the rule of six and recombinant viruses recovered from non-polyhexameric-length antigenomic cDNAs contain a biased distribution of correcting mutations. J. Virol. 77(1), 270-279 (2003). (Pubitemid 36004967)
91. Collins PL, Murphy BR. Respiratory syncytial virus: reverse genetics and vaccine strategies. Virology 296(2), 204-211 (2002). (Pubitemid 34713260)
92. Murphy BR, Collins PL. Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics. J. Clin. Invest. 110(1), 21-27 (2002). (Pubitemid 34743460)
93. Juhasz K, Murphy BR, Collins PL. The major attenuating mutations of the respiratory syncytial virus vaccine candidate cpts530/1009 specify temperature-sensitive defects in transcription and replication and a non-temperature-sensitive alteration in mRNA termination. J. Virol. 73(6), 5176-5180 (1999). (Pubitemid 29246783)
94. Juhasz K, Whitehead SS, Boulanger CA, Firestone CY, Collins PL, Murphy BR. The two amino acid substitutions in the L protein of cpts530/1009, a live-attenuated respiratory syncytial virus candidate vaccine, are independent temperature-sensitive and attenuation mutations. Vaccine 17(11-12), 1416-1424 (1999). (Pubitemid 29138808)
95. Whitehead SS, Firestone CY, Karron RA et al. Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity. J. Virol. 73(2), 871-877 (1999). (Pubitemid 29036737)
96. Skiadopoulos MH, Schmidt AC, Riggs JM et al. Determinants of the host range restriction of replication of bovine parainfluenza virus type 3 in rhesus monkeys are polygenic. J. Virol. 77(2), 1141-1148 (2003). (Pubitemid 36055536)
97. Skiadopoulos MH, Durbin AP, Tatem JM et al. Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes. J. Virol. 72(3), 1762-1768 (1998). (Pubitemid 28100725)
98. Feller JA, Smallwood S, Skiadopoulos MH, Murphy BR, Moyer SA. Comparison of identical temperature-sensitive mutations in the L polymerase proteins of sendai and parainfluenza3 viruses. Virology 276(1), 190-201 (2000).
99. Nolan SM, Surman SR, Amaro-Carambot E, Collins PL, Murphy BR, Skiadopoulos MH. Live-attenuated intranasal parainfluenza virus type 2 vaccine candidates developed by reverse genetics containing L polymerase protein mutations imported from heterologous paramyxoviruses. Vaccine 39(23), 4765-4774 (2005). (Pubitemid 41557327)
100. Nolan SM, Skiadopoulos MH, Bradley K et al. Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3′ genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primates. Vaccine 25(34), 6409-6422 (2007). (Pubitemid 47096752)
101. Madhi SA, Cutland C, Zhu Y et al. Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers. Vaccine 24(13), 2432-2439 (2006). (Pubitemid 43290427)